Everything below concerns degree of hydrolysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-18. Numbers and descriptions here follow the published literature rather than marketing material.
Whey protein hydrolysate is a dairy ingredient made by treating whey protein with proteolytic enzymes. The starting material is whey, the liquid remaining after cheese or casein production, and its main proteins include beta-lactoglobulin, alpha-lactalbumin, and bovine serum albumin. Enzyme action breaks peptide bonds, producing shorter peptides and some free amino acids. The result is not a single uniform substance; composition depends on whey source, enzyme type, hydrolysis conditions, and downstream filtration. Hydrolysates are often described by average peptide length or degree of hydrolysis rather than by one fixed molecular weight.
Compared with whey protein concentrate or isolate, hydrolysate has a smaller average peptide size and a higher proportion of low-molecular-weight fractions. This change can affect solubility, viscosity, osmolality, taste, and foam formation. Some hydrolysates are bitter because hydrophobic peptides are exposed during cleavage. The term hydrolysate does not indicate a guaranteed peptide profile; two products with the same reported hydrolysis value can differ in peptide sequence and residual intact protein. Commercial specifications usually state protein content, moisture, ash, fat, and microbiology, while peptide distribution may be reported as a range.
Whey protein hydrolysate powders are hygroscopic and can absorb moisture from air. Moisture uptake may lead to caking, reduced flowability, and gradual peptide degradation. Manufacturers typically specify cool, dry storage and sealed packaging to limit these changes. Water activity, rather than water content alone, is often monitored because it better predicts microbial and chemical stability. High temperatures can accelerate Maillard reactions between peptides and residual sugars, altering color and flavor. Exact shelf lives depend on formulation, packaging, and initial moisture, so they are usually determined by product-specific stability testing.
Analytical testing for whey protein hydrolysate focuses on peptide size distribution, degree of hydrolysis, protein content, moisture, ash, and microbiological quality. Size-exclusion chromatography and mass spectrometry can characterize peptide profiles, while Kjeldahl or combustion methods estimate total nitrogen and protein. Amino acid analysis quantifies free and total amino acids. Because peptide mixtures are complex, no single method captures every property, and results can vary between laboratories. Standardized methods and reference materials help improve comparability, but full sequence-level characterization remains uncommon in routine quality control.
Regulatory treatment of whey protein hydrolysate depends on the country and intended use. In many jurisdictions it is regulated as a food ingredient or food for special dietary use, not as a drug. Labeling rules govern allergen statements, protein content claims, and ingredient names. Some markets have specific rules for infant formula ingredients, where hydrolysates may be used for particular dietary purposes. Regulations generally focus on safety, truthful labeling, and manufacturing standards rather than on therapeutic effects. Scientific questions about specific peptide activities remain an active area of research rather than a settled regulatory category.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to light tan powder | Color can vary with hydrolysis and drying |
| Protein content | 70–90% dry basis | Lower if ash, lactose, or moisture remain |
| Degree of hydrolysis | Typically 5–35% | Partially and extensively hydrolyzed types differ |
| Solubility | Water-soluble | High across common food pH ranges, though peptide dependent |
| Common synonyms | Whey hydrolysate; hydrolyzed whey protein | Sometimes abbreviated WPH on labels |
Whey protein hydrolysate is a dairy-derived ingredient made by treating whey protein with enzymes or acid to break peptide bonds. The starting material is typically sweet whey or acid whey from cheese manufacture, which contains beta-lactoglobulin, alpha-lactalbumin, bovine serum albumin, and immunoglobulins. Hydrolysis shortens protein chains into peptides and free amino acids, changing solubility, viscosity, and taste. The extent of breakdown is described by degree of hydrolysis, a percentage of cleaved peptide bonds. This value influences functional and sensory properties but does not by itself define a specific molecular profile.
Commercial production usually begins with whey protein concentrate or isolate, not raw whey, to reduce fat and lactose. Food-grade proteases from bacterial or plant sources are added under controlled temperature and pH, then inactivated by heat or pH adjustment. The resulting liquid may be clarified, filtered, concentrated, and spray-dried into powder. Enzyme choice, reaction time, and pretreatment conditions create products with different peptide size distributions. Because these variables are proprietary and not standardized, two hydrolysates with the same degree of hydrolysis can differ in peptide sequences and mineral content.
Molecular weight distribution is a central compositional feature, and hydrolysis shifts the population toward lower-mass peptides, often below ten kilodaltons in extensively treated products. Enzyme choice, reaction time, temperature, pH, and enzyme-to-substrate ratio influence the peptide profile. Ultrafiltration or diafiltration may remove enzymes, salts, and smaller molecules. Because peptide size affects solubility, taste, foaming, and digestibility, manufacturers specify molecular weight ranges. However, two hydrolysates with similar average molecular weight can differ in peptide sequence and functional behavior.
Bitterness often increases with hydrolysis because hydrophobic peptides are exposed. Processing strategies therefore include selecting enzymes that cleave at specific sites, using exopeptidases to remove terminal hydrophobic residues, or blending hydrolysates with other ingredients. Allergenicity is another consideration: extensive hydrolysis can reduce IgE-binding epitopes, but it does not guarantee absence of allergenic potential. Regulatory frameworks vary in how they classify hydrolyzed whey for infant formula or sports products. Claims about reduced allergenicity or faster absorption depend on the specific product and study design, and are not uniform across all hydrolysates.
Composition tables often report protein content on a dry basis, ash, moisture, fat, and lactose. Because hydrolysis adds water to peptide bonds, the total mass yield can appear slightly higher than the original protein if residual salts and water are counted. Some products are further processed by ultrafiltration, spray drying, or decolorization, which alters mineral content and flavor. Product labels may distinguish partially hydrolyzed from extensively hydrolyzed whey, but these terms are not always defined by a single numerical threshold across regions.
Whey protein hydrolysate is a dairy ingredient made by treating whey protein with proteases that cleave peptide bonds. The starting material is typically whey protein concentrate or isolate, which contains beta-lactoglobulin, alpha-lactalbumin, and smaller amounts of bovine serum albumin and immunoglobulins. Hydrolysis shortens protein chains into peptides and free amino acids, changing solubility, viscosity, and flavor compared with intact whey protein. The extent of cleavage is commonly described by degree of hydrolysis, a percentage of broken peptide bonds relative to total bonds.
Enzyme choice influences the peptide size distribution and the resulting functional properties. Some proteases cut at specific amino acid residues, while others act more broadly, so two hydrolysates with the same degree of hydrolysis can differ in peptide sequences. Short peptides are generally more water-soluble and less likely to form gels under heat, although bitterness can increase when hydrophobic residues become exposed. The relationship between peptide length, taste, and bioactivity is an active area of study, and not all proposed effects are established in human trials.
Production begins with pasteurized whey, which is concentrated and sometimes defatted or demineralized before hydrolysis. Food-grade proteases, such as trypsin, chymotrypsin, pepsin, or microbial enzymes, are added under controlled conditions. After a target degree of hydrolysis is reached, the enzymes are inactivated by heat or pH adjustment. The liquor is then clarified, concentrated, and dried, usually by spray drying. Ultrafiltration or diafiltration may remove residual enzymes, salts, or very small peptides, depending on the intended specification.
The peptide profile affects functional behavior more than the total protein content alone. Short peptides can be more soluble across a range of pH values and may form clearer solutions than intact whey proteins. Bitterness often rises with higher degrees of hydrolysis because certain hydrophobic peptides are exposed. Foaming, gelation, and heat stability also change as molecular size decreases. These functional shifts make hydrolysates useful in beverages, clinical nutrition, and specialty foods, though the exact relationship between peptide sequence and sensory or physical properties remains an active area of study.
=== Crohn's disease === Three phenotypes, or categories of disease, are present in Crohn's disease: stricturing disease (which causes narrowing of the bowel), penetrating disease (which causes fistulae or abnormal connections of the bowel), and inflammatory disease (which primarily causes inflammation).
The word pharmacy is derived from Old French farmacie "substance, such as a food or in the form of a medicine which has a laxative effect" from Medieval Latin pharmacia from Greek pharmakeia (Ancient Greek: φαρμακεία) "a medicine", which itself derives from pharmakon (φάρμακον), meaning "drug, poison, spell" (which is etymologically related to pharmakos).
Measurement of the electrical activity of the heart (ECG) Measurement of blood pressure, heart rate, and body temperature Blood sampling Urine sampling Weight and height measurement Drug abuse testing Pregnancy testing It has been observed that participants in clinical trials are disproportionately white. Often, minorities are not informed about clinical trials. One recent systematic review of the literature found that race/ethnicity as well as sex were not well-represented nor at times even tracked as participants in a large number of clinical trials of hearing loss management in adults. This may reduce the validity of findings in respect of non-white patients by not adequately representing the larger populations.
Sources: en.wikipedia.org
6 June – BBC News reports that opposition to the Terminally Ill Adults (End of Life) Bill is growing among MPs, with a number who voted for it or abstained now saying they will vote against it. Following criticism of her performance at Prime Minister's Questions, Kemi Badenoch says she is "going to get better" as her party's leader, and is not "shy about self-criticism". Nathaniel Fried tells Politics South East that he resigned as head of Reform UK's Doge effort because the departure of Zia Yusuf left him with "a bit of doubt" about the project's future. Alexander Walker, the youngest member of Rhyl Town Council, is elected as the town's mayor at the age of 25. 7 June – Zia Yusuf announces he will return to Reform UK two days after resigning, and will run its Doge team. 8 June – The UK government says it intends to spend £86bn on the science and technology sector by the end of the current parliament. Reform's deputy leader, Richard Tice, insists the party knows "exactly what it is doing" following Zia Yusuf's departure and return. Speaking on BBC Scotland's Sunday Show, Scottish Labour leader Anas Sarwar accuses the Scottish National Party of running a "dishonest and disgraceful" campaign ahead of the Hamilton, Larkhall and Stonehouse by-election by attempting to push voters towards Reform UK, whose candidate came third in the election.
As of September 11, 2017, Teva remained the "world's biggest seller of generics medicines." On September 11, 2017, it was reported that they had selected Kåre Schultz as the new Teva CEO. A day later the company announced it would sell its Paragard contraceptive brand to Cooper Cos for $1.1 billion, with the funds being used to pay down debt. Days later the company announced further divestments: a sale of contraception, fertility, menopause and osteoporosis products to CVC Capital Partners Fund VI for $703 million and its emergency contraception brands for $675 million to Foundation Consumer Healthcare. By December, the company had announced a drastic 25 percent workforce reduction (greater than 14,000 employees) as part of a two-year cost-reduction strategy. Following considerable lobbying by the Israeli Government, from whom Teva received considerable tax breaks, and from Israel's labor federation, the Histadrut, Teva agreed to delay some of the layoffs in Israel. In October 2019, Teva faced criticism for making a "business decision to discontinue the drug" Vincristine, essential for the treatment of most childhood cancers according to the Food and Drug Administration.
Nir Ben-Tal [NBT1] (Hebrew: ניר בן-טל) is an Israeli computational biologist and professor in the School of Neurobiology, Biochemistry and Biophysics of the George S. Wise Faculty of Life Sciences, Tel Aviv University. He holds the Abraham E. Kazan Chair of Structural Biology, Tel Aviv University. His research focuses on computational structural biology, structural bioinformatics, protein evolution, and the relationships among protein sequence, structure, dynamics, and function.
Sources: en.wikipedia.org
== Post-World-War-II life and work == In 1947, aged 31, Crick began studying biology and became part of an important migration of physical scientists into biological research. This migration was made possible by the newly won influence of physicists such as Sir John Randall, who had helped win the war with inventions such as radar. Crick had to adjust from the "elegance and deep simplicity" of physics to the "elaborate chemical mechanisms that natural selection had evolved over billions of years." He described this transition as, "almost as if one had to be born again". According to Crick, the experience of learning physics had taught him something important—hubris—and the conviction that since physics was already a success, great advances should also be possible in other sciences such as biology. Crick felt that this attitude encouraged him to be more daring than typical biologists who tended to concern themselves with the daunting problems of biology and not the past successes of physics. For the better part of two years, Crick worked on the physical properties of cytoplasm at Cambridge's Strangeways Research Laboratory, headed by Honor Bridget Fell, with a Medical Research Council studentship, until he joined Max Perutz and John Kendrew at the Cavendish Laboratory. The Cavendish Laboratory at Cambridge was under the general direction of Sir Lawrence Bragg, who had won the Nobel Prize in 1915 at the age of 25.
Half-Life 2: Lost Coast is an additional level for the 2004 first-person shooter game Half-Life 2. Developed by Valve, it was released on October 27, 2005, as a free download for owners of Half-Life 2 on Steam. Players control Half-Life protagonist Gordon Freeman as he travels up a coastal cliff to destroy a Combine weapon in a monastery. Lost Coast is a technology demonstration showcasing the high-dynamic-range rendering implemented in the Source engine. It was designed with environments to emphasize these effects. Lost Coast was the first Valve game with a commentary mode, in which the developers explain elements of design as the player progresses through the level. The Lost Coast level was created for Half-Life 2, but was removed from the game. It was originally going to be a level in "Highway 17" where Gordon ends up in a strange place meeting a Fisherman. As a result, it has several minor story details that were not included in Half-Life 2. It received a generally positive reception, and there was consensus among reviewers that the new features included in Lost Coast should be integrated into future games released by Valve.
Transdermal estradiol bypasses the intestines and liver and hence the first-pass metabolism that is associated with oral administration. In addition, unlike oral estradiol, transdermal estradiol is not associated with supraphysiological concentrations of estrone or estrogen conjugates like estradiol sulfate, and transdermal estradiol does not have disproportionate effects on liver protein synthesis. In accordance, estradiol, at typical menopausal replacement dosages, has been found not to increase the risk of blood clots or insulin resistance, nor to affect hepatic SHBG, IGF-1, GHBP, IGFBP, and other protein production and by extension circulating hepatic protein levels. However, at higher doses, transdermal estradiol has been associated with a significantly higher incidence of stroke in postmenopausal women, probably due to blood clots. Another larger study did not find a significantly higher risk of blood clots with similar doses of transdermal estradiol however.
SS-Haupsturmfuhrer Alois Brunner, who played a significant role in the implementation of the Holocaust as the right-hand man of Adolf Eichmann, assisted al-Assad in organizing the Ba'athist secret police and trained them on Nazi Germany's torture practices. Such practices remained in use by 2021.
Sources: en.wikipedia.org
It is made from whey, the liquid byproduct of cheese or casein manufacture. The whey protein is treated with enzymes that cleave peptide bonds. The resulting mixture contains peptides of varying lengths plus some free amino acids.
Whey protein isolate is largely intact protein with a high protein content by dry weight. Hydrolysate has been enzymatically broken into smaller peptides, which can change taste, osmolality, and absorption behavior. Both can have similar total amino acid content, but their peptide profiles differ.
No. Hypoallergenic status depends on the extent of hydrolysis and the residual allergenic protein fragments. Regulatory bodies set specific criteria for products labeled hypoallergenic or extensively hydrolyzed. A hydrolysate not meeting those criteria may still contain allergenic epitopes.
It is generally stored in a sealed container in a cool, dry place away from strong odors. Moisture and heat can cause caking, flavor changes, and peptide degradation. Product-specific labels and stability data should guide actual storage conditions.